Skip to main content

Advertisement

Table 3 Secondary efficacy endpoints in the current study

From: Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

  No-Tx Ctrl* Pre-Tx Ctrl* Tx P value
Severity 3.50 (N = 18) 3.05 (N = 115) 5.98 (N = 115) P < 0.0001 (both controls)
On a scale of 1–7a
Interference with daily life 3.71 (N = 14) 3.20 (N = 59) 6.14 (N = 59) P < 0.0001 (both controls)
On a scale of 1–7b
Pain 3.74 (N = 19) 3.13 (N = 105) 5.84 (N = 105) P < 0.0001 (both controls)
On a scale of 1–7c
  1. Tx treatment
  2. * We excluded those participants that had 7 in in the pre-treatment or no-treatment control groups, or did not respond to the question, that is, we excluded those that did not have the specific symptom
  3. aWhere 1 is “very bad” and 7 is “not bad at all”
  4. bWhere 1 is “interfered all the time” and 7 is “did not interfere”
  5. cWhere 1 is “very painful” and 7 is “no pain at all”